000125705 001__ 125705
000125705 005__ 20240303002508.0
000125705 0247_ $$2doi$$a10.2217/imt-2016-0083
000125705 0247_ $$2pmid$$apmid:27485076
000125705 0247_ $$2ISSN$$a1750-743X
000125705 0247_ $$2ISSN$$a1750-7448
000125705 0247_ $$2altmetric$$aaltmetric:17890435
000125705 037__ $$aDKFZ-2017-01831
000125705 041__ $$aeng
000125705 082__ $$a610
000125705 1001_ $$aDick, J.$$b0
000125705 245__ $$aUse of LDH and autoimmune side effects to predict response to ipilimumab treatment.
000125705 260__ $$aLondon$$bFuture Medicine Ltd$$c2016
000125705 3367_ $$2DRIVER$$aarticle
000125705 3367_ $$2DataCite$$aOutput Types/Journal article
000125705 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522048647_13615
000125705 3367_ $$2BibTeX$$aARTICLE
000125705 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125705 3367_ $$00$$2EndNote$$aJournal Article
000125705 520__ $$aIpilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation.In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data.A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit.Changes in LDH level and side effects correlate with response to therapy and survival.
000125705 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000125705 588__ $$aDataset connected to CrossRef, PubMed,
000125705 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal
000125705 650_7 $$2NLM Chemicals$$aBiomarkers, Pharmacological
000125705 650_7 $$2NLM Chemicals$$aCTLA-4 Antigen
000125705 650_7 $$06T8C155666$$2NLM Chemicals$$aipilimumab
000125705 650_7 $$09007-41-4$$2NLM Chemicals$$aC-Reactive Protein
000125705 650_7 $$0EC 1.1.1.27$$2NLM Chemicals$$aL-Lactate Dehydrogenase
000125705 7001_ $$aLang, N.$$b1
000125705 7001_ $$0P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aSlynko, A.$$b2$$udkfz
000125705 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, A.$$b3$$udkfz
000125705 7001_ $$aSchulz, C.$$b4
000125705 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, A.$$b5$$udkfz
000125705 7001_ $$aEnk, A. H.$$b6
000125705 7001_ $$0P:(DE-HGF)0$$aHassel, J. C.$$b7
000125705 773__ $$0PERI:(DE-600)2495964-9$$a10.2217/imt-2016-0083$$gVol. 8, no. 9, p. 1033 - 1044$$n9$$p1033 - 1044$$tImmunotherapy$$v8$$x1750-7448$$y2016
000125705 909CO $$ooai:inrepo02.dkfz.de:125705$$pVDB
000125705 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000125705 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000125705 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000125705 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000125705 9141_ $$y2016
000125705 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125705 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125705 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125705 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bIMMUNOTHERAPY-UK : 2015
000125705 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125705 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125705 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125705 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125705 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000125705 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000125705 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x1
000125705 980__ $$ajournal
000125705 980__ $$aVDB
000125705 980__ $$aI:(DE-He78)C060-20160331
000125705 980__ $$aI:(DE-He78)E060-20160331
000125705 980__ $$aUNRESTRICTED